Subacute cutaneous lupus erythematosus
ICD-10 L93.1 · ICD-11 EB50

Treatment of Subacute Cutaneous Lupus Erythematosus with Severe or Widespread Skin Lesions

This protocol addresses subacute cutaneous lupus erythematosus (SCLE) in patients whose disease involves severe or widespread skin lesions, those at risk of scarring, or those at risk of developing systemic disease — situations that call for prompt, structured systemic management.

Clinical scenario: Severe or widespread cutaneous lupus erythematosus skin lesions, or risk of scarring, or risk of development of systemic disease.

Antimalarials are recommended as first-line and long-term systemic treatment in this population, particularly where scarring or progression to systemic involvement is a concern. In patients with severe or widespread active lesions, systemic corticosteroids may be added alongside antimalarial therapy.

Treatment approach

When monotherapy with a first-choice antimalarial is not sufficient, combination therapy involving quinacrine may be considered to achieve synergistic efficacy. For patients with a contraindication to standard antimalarials, an alternative quinacrine-based approach is outlined. The complete regimen — including the specific combinations, sequencing, and contraindication management — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

  • We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
  • In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
  • If monotherapy with HCQ or CQ is not successful, quinacrine (100 mg/day) may be added, resulting in synergistic efficacy, without increasing the risk of retinopathy.
  • In refractory cases, we recommend to add quinacrine to either HCQ or CQ.
  • In cases of contraindication for HCQ or CQ (e.g., retinopathy), monotherapy with quinacrine is recommended.
View source ↗